Introduction
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL, also known as Apo2L) is a member of TNF family. 1, 2 Similar to other TNF family molecules such as TNF-a or Fas-L, TRAIL is a type of transmembrane protein with an extracellular domain, which can bind with its specific ligand of cell surface receptors: TRAIL receptor 1(DR4), TRAIL receptor 2(DR5), TRAIL receptor 3(DcR1), TRAIL receptor 4(DcR2) and osteoprotegrin. 3 TRAIL mediates apoptosis in a diverse manner; little or no toxic effect on normal cells have been reported. 4 In contrast to Fas-L, the administration of which causes lethal liver damage, injection of TRAIL did not result in severe general toxicity, although it has been reported recently to induce damage in human hepatocytes and normal brain tissue. Binding of TRAIL to its effective receptors (DR4 and DR5) contributes to recruitment of adaptor molecule Fas-accociated Death Domain (FADD), which in turn results in cleavage and activation of caspase-8 and caspase-3. Activated caspase-3 can proteolytically cleave a series of cellular proteins, including poly (ADP-ribose) polymerase (PARP), lamins and so on, resulting in morphologic features of apoptosis. 5, 6 However, decoy receptors (DcR1, DcR2 and osteoprotegrin), which have no cytoplasmic death domain or truncated ones, could not transduce death signals to cytoplasm. 7, 8 By contrast, the expression of intracellular inhibitors of apoptosis has been proposed to be an essential determinant of cell sensitivity to TRAIL. Higher expression of cellular FLICE-inhibitory protein (c-FLIP), 9 Bcl-2 10 or IAP family proteins including cIAP1, cIAP2 or XIAP 11, 12 could inhibit TRAIL-induced caspase activation, result in cell survival of TRAIL treatment.
Although normal dose of chemotherapeutic agents effectively kill tumor cells via different pathway, several side effects, such as agranulocytosis, nausea and vomiting etc may occur after therapy. Recently, several chemical drugs have been reported to enhance TRAILinduced apoptosis in malignant cells. However the mechanisms of these drugs and the effects of individual cases are complicated. In our research, we attempted to elucidate the mechanisms of apoptosis sensitization in human prostate cancer cell line LNCaP to TRAIL and subtoxic concentration of doxorubicin.
Materials and methods

Reagents and antibodies
Soluble human TRAIL was purchased from R&D system (Minneapolis, MI, USA). Doxorubicin was from Topo-GEN (Columbus, OH, USA). Mouse anticaspase-8 monoclonal antibody (mAb) (5F7), mouse anti-FADD mAb and mouse anti-XIAP mAb were purchased from MBL (Japan). PE-conjugated mouse anti-DR4, DR5, DcR1 and DcR2 mAb, affinity-purified mouse IgG1 Isotype control were from eBiosciences (USA). Mouse anti-Bcl-2 mAb, rabbit anti-FLIP L polyclonal antibody (pAb) were from BD Bioseience (USA). Peroxidase-linked goat antirabbit IgG-HRP antibody were from Santa Cruz Biotechnology, Inc. (USA). Peroxidase-linked sheep anti-mouse IgG1-HRP antibody was from Amersham Pharmacia Biotech (Japan). Mouse anticaspase-3 mAb is from Immunotech (France). Rabbit antiactin pAb was from Sigma (USA).
Cell culture
Human prostate cancer cell LNCaP was purchased from ATCC and maintained in RPMI 1640 medium supplemented with 10% heat-inactivated FBS and 0.1 mg/ml kanamycin at 371C in a humidified 5% CO 2 atmosphere.
Measurement of cell viability
Cells were incubated with recombinant human TRAIL, doxorubicin, Z-IETD-fmk (R&D Systems Inc., USA), goat anti-DR4, DR5 antagonist pAb (DAKO, Japan) or in combination for indicated time at 371C. Apoptosis was measured by flow cytometry using propidium iodide (PI) staining. In each assay, Z-IETD-fmk or anti-DR4, DR5 Ab were added 1 h before addition of TRAIL. According to manufacturer's recommendation, cells were stained and PI orange (FL-2) fluorescence emission were recorded by FACScan flowcytometer (Becton Dickson, Japan), the results were analyzed using CELLQuest software.
Flow cytometric analysis of TRAIL receptors
The expressions of TRAIL receptors on cell surface were measured using flow cytometric analysis. In brief, a total of 1 Â 10 6 cells were incubated with or without each agent in a 24-well plate. Then PE-conjugated anti-DR4, DR5, DcR1 and DcR2 Ab or mouse IgG control were added and incubated for 40 min on ice in dark. After washing twice with ice-chilled PBS, surface expression of TRAIL receptors were determined using FACScan flowcytometer.
Western blotting
Proteins (30 mg) obtained by SDS lysis were separated on 12.5% polyacrylamide gel. After transfer to a polyvinylidene difluoride membrane and incubated overnight at 41C with 5% bovine serum albumin (BSA) in PBS to block nonspecific immunoglobulins, the membrane was incubated for 1 h at room temperature with anticaspase-8, anti-FLIP L , anti-Bcl-2, anti-XIAP anticaspase-3 or anti-PARP Ab. After washing, the membrane was incubated with HRP-conjugated secondary Ab for 1 h at room temperature. Specific bands were detected using ECL, according to manufacturer's protocol (Amersham Life Science, Japan).
Statistics
Data analysis was done using Statview software. A twosided Student's t-test was used to determine differences between groups. Multivariate analysis was performed with the Cox proportional hazard model.
Results
Low dosage of doxorubicin enhanced TRAILinduced apoptosis in human prostate cancer cell line LNCaP
LNCaP cells were treated with 100 ng/ml human recombinant TRAIL and 0.86 mmol/L doxorubicin or in combination in different time. At 24 h after incubation, cell viability under TRAIL treatment was 88%, that under doxorubicin treatment was 91% while in combination group, cell viability was 68%, which was lower than other groups significantly (Po0.05) (Figure 1 ).
Caspase-8 and caspase-3 activation were necessary for TRAIL-induced apoptosis Cells were pretreated with 10 mg/ml Z-IETD-fmk for 1 h or not and subsequently incubated with TRAIL (100 ng/ml), doxorubicin (0.86 mmol/L) or in combination for 6 h. Caspase-8 and caspase-3 activation were proved by Both DR4 and DR5 were responsible for TRAILmediated signal transduction and could be upregulated in the presence of doxorubicin Cells were pretreated with DR4 and DR5 antagonist antibodies (1 : 1000) for 2 h or not, then incubated with TRAIL 100 ng/ml and 0.86 mmol/L doxorubicin in different time. Apoptosis were inhibited significantly under certain condition (Figure 3) . Moreover, cells were treated with 0.86 mmol/L doxorubicin for 6 h and surface expression of TRAIL receptors were evaluated using PEconjugated anti-DR4 and DR5 monoclonal antibody by flow cytometry. As shown in Figure 4 , cell surface of DR4 and DR5 expressed brightly after incubation with certain concentration of doxorubicin in indicated time. 
Discussion
Few studies have focused on the TRAIL effects on prostate cancer cells. In the present study, we sought to examine human prostate cancer cell line LNCaP for their susceptibility to TRAIL-induced apoptosis. We have demonstrated that TRAIL was not able to induce apoptosis in the cells, while cotreatment with low dosage of doxorubicin increased the sensitivity to TRAIL under certain conditions. TRAIL triggers apoptosis in tumor cells by binding to its cognate death receptors on cell surface. In our experiments, LNCaP expressed both DR4 and DR5. However, lower levels of expression of decoy receptors did not show any correlation with their sensitivity to TRAIL. Of the two death receptors (DR4 and DR5), it seemed that they took same effort to TRAIL-induced apoptosis, by partial inhibition of apoptosis via antagonist DR4 or DR5 antibody treatment, a little difference with our previous results. 13 Doxorubicin shows anticancer efficacy, however, severe cardiac toxiticity limits its use in clinic. Recent studies revealed that doxorubicin could increase DR5 expression in human colon cancer cells.
14 Here, to show the synergic effects of this drug in TRAIL-induced apoptosis, subtoxic concentrations used in this study (0.86 mmol/L) have been determined by studies of cell viability in our previous experiments published elsewhere.
As expected, we found that both DR4 and DR5 could be upregulated under subtoxic concentration of doxorubicin stimulation, while antagonist antibody to DR4 and DR5 blocked the apoptosis triggered by TRAIL and doxorubicin. This observation strongly suggests that DR4 and DR5 play an important role in TRAIL-induced apoptosis and their expression by doxorubicin might be responsible for recruitment of TRAIL sensitivity in LNCaP cells. Although the expression of DcR1 and DcR2 has been reported to be one of the reasons for the resistance to TRAIL-induced apoptosis, 1 their expression in our study were minimal and did not correlate with susceptibility to TRAIL.
TRAIL-induced apoptosis in LNCaP is characterized by caspase-8 and caspase-3 activation, implicating that these caspases are necessary for signal transduction in TRAIL-induced apoptosis, as reported previously. 15 Procaspase-8 recruits to FADD, cleavages into active form and further activates procaspase-3, thus, triggers programmed cell death events in nuclei ( Figure 6 ). It is Caspase-9 Figure 6 Model of TRAIL-induced cell apoptosis and indispensable proteins involved in signal transduction. After TRAIL binding with DR4 and DR5, an adaptor proteins complex was formed consisting of FADD, which resulted in autocleavage of procaspase-8. Furthermore, activation of caspase-3 was triggered either by mitochondria pathway which involved cytochrome-C release and caspase-9 activation or directly by active form of caspase-8, eventually leading to irreversible apoptosis. c-FLIP, Bcl-2 and XIAP functioned as antiapoptotic proteins, which inhibited apoptosis at the level of caspase-8, mitochondria and caspase-3, respectively. 16 Expression of c-FLIP L in some cancer cells was correlated with their sensitivity to TRAIL, 17 but not in others. 14, 18 We found that c-FLIP L was constitutionally expressed in LNCaP cells and interestingly; it could be downregulated following doxorubicin treatment at the concentration that enhances TRAIL-induced apoptosis. These dramatic changes were quite consistent with the results originated from DISC formation analysis in previous reports. 19 High c-FLIP/caspase-8 ratio was supposed to be related to TRAIL resistance, 20, 21 and it seems to be proven in our study, in which c-FLIP L was rapidly processed after doxorubicin treatment in LNCaP cells. Thus, it is very possible that c-FLIP L could be directly involved in regulating TRAIL-induced apoptosis in LNCaP cells.
A second candidate is XIAP, a member of the IAP family, which functions as suppressor of apoptosis. [22] [23] [24] Members of the IAP family were found to directly bind and selectively block the activation of caspase-3, caspase-7 and caspase-9 but not caspase-8 and caspase-10. 25 However, we found that the expression of XIAP remained stable under certain stimulation and it suggests that this protein was unlikely to play a key role in enhancing and restoring TRAIL sensitivity in our cells.
Moreover, TRAIL-mediated cell death can involve the cleavage of some antiapoptotic members of the Bcl family such as Bcl-2, which was able to translocate into mitochondria preventing release of cytochrome c, consequently activating caspase-9 and caspase-3. The results of our study, showed that Bcl-2 could not be influenced by subtoxic concentration of doxorubicin and suggested that Bcl-2 was quite stable and constitutionally expressed in LNCaP cells.
In summary, our studies have shown that TRAILinduced apoptosis in the presence of low concentrations of doxorubicin in human prostate cancer cell line LNCaP, suggest some therapeutic potential. TRAIL-mediated cell death via both DR4 and DR5 triggered caspase-8 and caspase-3 activation. Upregulation of DR4 and DR5, downregulation of c-FLIP might contribute to restoration of TRAIL sensitivity in LNCaP cells with combination treatment of doxorubicin. The ability of subtoxic concentration of chemotherapeutic drugs to restore TRAILmediated pathway to death in cell lines that are resistant to TRAIL-induced cytotoxicity suggest that combination of an anticancer drug with TRAIL may lower the signaling threshold required for TRAIL-induced apoptosis and enhance TRAIL-based therapeutic strategy.
